Citrin Deborah E, Prasanna Pataje G S, Walker Amanda J, Freeman Michael L, Eke Iris, Barcellos-Hoff Mary Helen, Arankalayil Molykutty J, Cohen Eric P, Wilkins Ruth C, Ahmed Mansoor M, Anscher Mitchell S, Movsas Benjamin, Buchsbaum Jeffrey C, Mendonca Marc S, Wynn Thomas A, Coleman C Norman
a Radiation Oncology Branch, Center for Cancer Research, Bethesda, Maryland.
b Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland.
Radiat Res. 2017 Jul;188(1):1-20. doi: 10.1667/RR14784.1. Epub 2017 May 10.
A workshop entitled "Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate" (held in Rockville, MD, September 19, 2016) was organized by the Radiation Research Program and Radiation Oncology Branch of the Center for Cancer Research (CCR) of the National Cancer Institute (NCI), to identify critical research areas and directions that will advance the understanding of radiation-induced fibrosis (RIF) and accelerate the development of strategies to mitigate or treat it. Experts in radiation biology, radiation oncology and related fields met to identify and prioritize the key areas for future research and clinical translation. The consensus was that several known and newly identified targets can prevent or mitigate RIF in pre-clinical models. Further, basic and translational research and focused clinical trials are needed to identify optimal agents and strategies for therapeutic use. It was felt that optimally designed preclinical models are needed to better study biomarkers that predict for development of RIF, as well as to understand when effective therapies need to be initiated in relationship to manifestation of injury. Integrating appropriate endpoints and defining efficacy in clinical trials testing treatment of RIF were felt to be critical to demonstrating efficacy. The objective of this meeting report is to (a) highlight the significance of RIF in a global context, (b) summarize recent advances in our understanding of mechanisms of RIF,
由美国国立癌症研究所(NCI)癌症研究中心(CCR)的辐射研究项目和放射肿瘤学分支组织了一场题为“辐射诱导的纤维化:机制与缓解机会”的研讨会(于2016年9月19日在马里兰州罗克维尔举行),以确定关键的研究领域和方向,这些领域和方向将推动对辐射诱导纤维化(RIF)的理解,并加速减轻或治疗该病症策略的开发。辐射生物学、放射肿瘤学及相关领域的专家齐聚一堂,确定未来研究和临床转化的关键领域并对其进行优先级排序。达成的共识是,在临床前模型中,若干已知和新发现的靶点可预防或减轻RIF。此外,需要开展基础研究、转化研究以及有针对性的临床试验,以确定用于治疗的最佳药物和策略。人们认为,需要设计出优化的临床前模型,以更好地研究预测RIF发生的生物标志物,以及了解在损伤出现时何时需要启动有效治疗。在测试RIF治疗方法的临床试验中,整合适当的终点指标并定义疗效被认为对于证明疗效至关重要。本会议报告的目的是:(a)强调RIF在全球范围内的重要性;(b)总结我们对RIF机制理解的最新进展,